BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 32898301)

  • 1. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
    Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
    Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
    Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
    J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
    Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
    Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
    Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
    Levink IJM; Klatte DCF; Hanna-Sawires RG; Vreeker GCM; Ibrahim IS; van der Burgt YEM; Overbeek KA; Koopmann BDM; Cahen DL; Fuhler GM; Wuhrer M; Bonsing BA; Tollenaar RAEM; Vleggaar FP; Vasen HFA; van Leerdam ME; Bruno MJ; Mesker WE
    Pancreatology; 2022 May; 22(4):497-506. PubMed ID: 35414481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
    Gebrehiwot AG; Melka DS; Kassaye YM; Gemechu T; Lako W; Hinou H; Nishimura SI
    BMC Cancer; 2019 Jun; 19(1):588. PubMed ID: 31208374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation.
    Sethi MK; Kim H; Park CK; Baker MS; Paik YK; Packer NH; Hancock WS; Fanayan S; Thaysen-Andersen M
    Glycobiology; 2015 Oct; 25(10):1064-78. PubMed ID: 26085185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased α1-3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer.
    Balmaña M; Giménez E; Puerta A; Llop E; Figueras J; Fort E; Sanz-Nebot V; de Bolós C; Rizzi A; Barrabés S; de Frutos M; Peracaula R
    J Proteomics; 2016 Jan; 132():144-54. PubMed ID: 26563517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
    Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
    Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthy human serum N-glycan profiling reveals the influence of ethnic variation on the identified cancer-relevant glycan biomarkers.
    Gebrehiwot AG; Melka DS; Kassaye YM; Rehan IF; Rangappa S; Hinou H; Kamiyama T; Nishimura SI
    PLoS One; 2018; 13(12):e0209515. PubMed ID: 30592755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer.
    Liu Y; Wang C; Wang R; Wu Y; Zhang L; Liu BF; Cheng L; Liu X
    J Proteomics; 2018 Jun; 181():160-169. PubMed ID: 29674015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
    Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
    J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
    SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
    Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
    BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.